Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of AZD9550 and AZD6234 Formulations in Overweight/Obese Participants
NCT07911514Phase 1Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AZD9550 and lenbelintide in obesity (5 arms), sponsored by AstraZeneca. Primary endpoints: Maximum observed plasma concentration at Day 22, Area under the curve from time 0 to the time of last quantifiable concentration at Day 22 and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
AZD9550lenbelintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07911514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07911514.